---
title: "Acrux Releases Top 20 Option Holders and Distribution Schedule"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/228788976.md"
description: "Acrux Limited (AU:ACR) has announced the release of its top 20 option holders and distribution schedule for a new class of quoted securities, following its Appendix 2A Application. This update, based on the Options Prospectus dated January 17, 2025, reflects Acrux's commitment to enhancing its financial operations and market presence. The pharmaceutical company, with over 25 years of experience, focuses on developing topical pharmaceuticals and is positioned for partnerships and product development. Current market cap stands at $8.24M."
datetime: "2025-02-19T03:28:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/228788976.md)
  - [en](https://longbridge.com/en/news/228788976.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/228788976.md)
generator: "portal-rs"
---

# Acrux Releases Top 20 Option Holders and Distribution Schedule

### Discover the Best Stocks and Maximize Your Portfolio:

-   See what stocks are receiving strong buy ratings from top-rated analysts.
-   Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Acrux Limited ( (AU:ACR) ) has shared an update.

Acrux Limited has released information regarding the top 20 option holders and distribution schedule for its new class of quoted securities, following its Appendix 2A Application for Quotation of Securities. This announcement outlines the terms and conditions as per the Options Prospectus dated 17 January 2025. The release signifies Acrux’s ongoing efforts to enhance its financial operations and market presence, which may impact its industry positioning and offer potential opportunities for stakeholders.

**More about Acrux Limited**

Acrux Limited is a pharmaceutical company specializing in developing and commercializing topical pharmaceuticals. With over 25 years of experience, Acrux has successfully launched several topically applied pharmaceutical products in the US and Europe. The company focuses on developing generic products for the US market, leveraging its in-house laboratories, GMP manufacturing suite, and commercial expertise to offer affordable healthcare solutions. Acrux is open to collaboration and is well-positioned for partnerships and product development.

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** $8.24M

For a thorough assessment of ACR stock, go to TipRanks’ Stock Analysis page.

## Trending Articles:

-   ‘Stay Bullish,’ Says Morgan Stanley About Tesla Stock
-   Palantir or AMD: Cathie Wood Makes a Move on One High-Potential AI Stock
-   ‘A No-Brainer Bargain,’ Says Top Investor About Nvidia Stock

### Related Stocks

- [ACR.AU](https://longbridge.com/en/quote/ACR.AU.md)

## Related News & Research

- [Acrux Plans Major Equity Issue to Bolster Capital Base](https://longbridge.com/en/news/285861885.md)
- [Vibra Energia launches BRL 1.4 billion unsecured debenture offering](https://longbridge.com/en/news/298116619.md)
- [Barclays Reaffirms Their Hold Rating on Swedbank (0H6T)](https://longbridge.com/en/news/298084297.md)
- [Strong job gains signal Fed hike as Trump levels new rate-cut demand](https://longbridge.com/en/news/298080405.md)
- [Is Camtek (CAMT) Options Frenzy Quietly Reframing Its Near‑Term Earnings Story?](https://longbridge.com/en/news/298114664.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**